46249-41-6

Usage

Uses

Used in Pharmaceutical Industry:
4-(Aminosulfonyl)benzenesulfonyl chloride is used as a building block for the synthesis of various pharmaceuticals. Its ability to introduce sulfonamide groups into organic molecules makes it a valuable reagent in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(Aminosulfonyl)benzenesulfonyl chloride is utilized as a key intermediate in the production of agrochemicals. Its sulfonating properties allow for the creation of compounds with specific pesticidal or herbicidal activities.
Used in Dye Industry:
4-(Aminosulfonyl)benzenesulfonyl chloride is employed as a starting material in the synthesis of dyes. Its chemical structure contributes to the development of dyes with unique color properties and stability.
Used in Organic Synthesis:
As a versatile reagent in organic chemistry, 4-(Aminosulfonyl)benzenesulfonyl chloride is used in a variety of organic synthesis processes. Its ability to form sulfonamide groups makes it a useful component in the creation of complex organic molecules for research and industrial applications.

InChI:InChI=1/C6H6ClNO4S2/c7-13(9,10)5-1-3-6(4-2-5)14(8,11)12/h1-4H,(H2,8,11,12)

Upstream product

• 35282-78-1 4-(aminosulphonyl)benzenediazonium chloride 
• 63-74-1 sulfanilamide 
• 7632-00-0 sodium nitrite 

Downstream Products

• 16993-45-6 benzene-1,4-disulfonamide 
• 90648-98-9 p-(2,3-Dihydroxypropylsulfamoyl)benzolsulfonamid 
• 32548-70-2 Benzene-1,4-disulfonic acid 1-amide 4-hexylamide 
• 13337-94-5 4-(4-methyl-3,5-dioxo-[1,2,4]oxadiazinane-2-sulfonyl)-benzenesulfonamide 
• 90197-90-3 4-Sulfamoyl-benzol-sulfonsaeure-⁽¹⁾-ethylamid 
• 32548-68-8 Benzene-1,4-disulfonic acid 1-amide 4-dipentylamide 
• 57864-99-0 4-[N'-(1,1-dioxo-1,2(4)-dihydro-1λ⁶-benzo[1,2,4]thiadiazine-3-carbonyl)-hydrazinosulfonyl]-benzenesulfonamide 
• 165669-28-3 N-(1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide 
• 114723-11-4 N,N'-bis-trichlorophosphoranylidene-benzene-1,4-disulfonamide 
• 100367-47-3 N,N'-bis-dichlorophosphoryl-benzene-1,4-disulfonamide 
• 122649-06-3 N,N'-(benzene-1,4-disulfonyl)-bis-amidophosphoric acid tetramethyl ester 
• 116378-34-8 N,N'-(benzene-1,4-disulfonyl)-bis-amidophosphoric acid tetraphenyl ester 
• 32529-42-3 Benzene-1,4-disulfonic acid 1-(acetyl-amide) 4-dibutylamide 
• 1073637-59-8 N-(N,N-diethylaminoethyl)benzene-1,4-bis(sulphonamide) 

Relevant academic research and scientific papers

Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII

4-Sulfamoyl-N-(3-morpholinopropyl)benzamide (I-1), N-(3-morpholinopropyl)benzene-1,4-disulfonamide (I-2) and N-(4-diethylaminoethoxybenzyl)benzene-1,4-bis(sulfonamide (I-3), were prepared and assayed as inhibitors of four carbonic anhydrase (CA) isoenzyme

Benzenesulfonamide derivatives and pharmaceutical composition thereof

The present invention is related to derivatives of benzenesulfonamide represented by formula (I), and the pharmaceutical composition thereof. In addition, the benzenesulfonamide derivatives disclosed in the present invention can serve as potential cell cycle inhibitors, and thereby these benzenesulfonamide derivatives and the pharmaceutical composition thereof can be antitumor drug candidates, which might aim at cell cycle. Particularly, the benzenesulfonamide derivatives disclosed in the present invention may function as antitumor drugs to treat solid cancers.

NOVEL ANALGESIC THAT BINDS FILAMIN A

A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R1 and R2 are substituents, and n, W, X and Y are defined within.

SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE

Substituted sulphonamides having the general formula (I) and salts, hydrates and solvates thereof were prepared and described, wherein R1 isCO or SO2 and R2 is NH or O and where R represents linear or cyclic aliphatic chain and n represents number of linking aliphatic chain carbons (n can be 0, 1, 2 or 3), which are useful in the manufacture of the medicaments due to the carboanhydrase inhibition. These compounds are prepared by nucleophilic reaction of an amine with 4-sulfamoylbenzenesulphonyl chloride in the presence of triethylamine excess in tetrahydrofurane or in ether at temperature 0 to 20 °C. The compounds show an antiglaucomatic activity.

CRYSTAL OF TWO-RING HETEROCYCLIC SULFONAMIDE COMPOUND

Novel β-type crystal of N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide of the formula: characterized in, for example, that in powder X-ray diffractometry, it has a diffraction peak at a diffraction angle (2θ±0.2°) of 18.4°. This crystal has favorable properties, such as high solubility in buffer solutions and various organic solvents, and is suitable to an active ingredient of a pharmaceutical composition for use as an antitumor agent, an activated lymphocyte suppressor or an eating enhancer.

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

INTEGRIN EXPRESSION INHIBITORS

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Sulfonamide-containing indole compounds

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.

Cyclic N-substituted derivatives of 1,4-benzene disulphonamide

Compounds of the formulae: SPC1 And the salts thereof with pharmaceutically acceptable cations wherein n and m are each two or three; X is oxygen or sulphur; R2 and R3, when taken separately, are each hydrogen or alkyl having 1 to 4 carbon atoms; R2 and R3, when taken together, are alkylene having 2 to 4 carbon atoms; Y is methylene or a single bond; R4 and R5, when taken separately, are each hydrogen, hydroxy or alkoxy having 1 to 5 carbon atoms, and R4 and R5, when taken together, are oxo or alkylene dioxy having 2 to 4 carbon atoms, each oxygen atom in R4 and R5, when taken separately, and in R4 and R5, when taken together, being separated from the nitrogen atom of the heterocyclic ring by two or more carbon atoms, said compounds being cerebral vasodilators.